Criteria | Ruxolitinib duration | Cytopenias | Spleen size |
---|---|---|---|
Relapsed |  ≥ 3 months | – | Regrowth < 10% SVR or < 30% decrease in spleen size by palpation from baseline following an initial response |
Refractory |  ≥ 3 months | – |  < 10% SVR or < 30% decrease in spleen size by palpation from baseline |
Intolerant |  ≥ 28 days | New grade ≥ 3 thrombocytopenia, anemia, hematoma/hemorrhage or RBC transfusion requirement ≥ 2 units/month for 2 months | – |